• Proceedings of the Korean Society of Applied Pharmacology
• /
• 2006.11a
• /
• pp.139-145
• /
• 2006

Kaneka Corporation (Kaneka) has been manufacturing CoQ10 under GMP regulation since 1977. Kaneka has a sophisticated quality control system and has been supplying high quality CoQ10 materials to the worldwide customers (Kaneka CoQ10) for about 30 years. Kaneka CoQ10 is characterized by a lot of safety data, which are derived from clinical trials with healthy volunteers (single-dose and 4-week multi-dose safety studies), animal studies (13-week sub-chronic study in dogs and 52-week chronic study in rats), three types of mutagenicity test, six type of skin irritation test (for cosmetics), and others. The risk assessment of CoQ10 was performed by Council for Responsible Nutrition (USA). They reviewed many of available clinical data including clinical trials using Kaneka Q10, and concluded that the upper level for supplements (ULS) of CoQ10 is 1,200 mg/day (Hathcock and Shao. 2006, Regulatory Toxicology and Pharmacology, 45, 282 - 288).

• 한국약용작물학회:학술대회논문집
• /
• 2006.11a
• /
• pp.139-145
• /
• 2006

Kaneka Corporation (Kaneka) has been manufacturing CoQ10 under GMP regulation since 1977. Kaneka has a sophisticated quality control system and has been supplying high quality CoQ10 materials to the worldwide customers (Kaneka CoQ10) for about 30 years. Kaneka CoQ10 is characterized by a lot of safety data, which are derived from clinical trials with healthy volunteers (single-dose and 4-week multi-dose safety studies), animal studies (13-week sub-chronic study in dogs and 52-week chronic study in rats), three types of mutagenicity test, six type of skin irritation test (for cosmetics), and others. The risk assessment of CoQ10 was performed by Council for Responsible Nutrition (USA). They reviewed many of available clinical data including clinical trials using Kaneka Q10, and concluded that the upper level for supplements (ULS) of CoQ10 is 1,200mg/day (Hathcock and Shao. 2006, Regulatory Toxicology and Pharmacology, $\underline{45}$, 282 - 288).

• Advances in Traditional Medicine
• /
• v.10 no.4
• /
• pp.239-253
• /
• 2010

Coenzyme $Q_{10}$ ($CoQ_{10}$, or ubiquinone) is an electron carrier of the mitochondrial respiratory chain (electron transport chain) with antioxidant properties. In view of the involvement of $CoQ_{10}$ in oxidative phosphorylation and cellular antioxidant protection a deficiency in this quinone would be expected to contribute to disease pathophysiology by causing a failure in energy metabolism and antioxidant status. Indeed, a deficit in $CoQ_{10}$ status has been determined in a number of neuromuscular and neurodegenerative disorders. Primary disorders of $CoQ_{10}$ biosynthesis are potentially treatable conditions and therefore a high degree of clinical awareness about this condition is essential. A secondary loss of $CoQ_{10}$ status following HMG-CoA reductase inhibitor (statins) treatment has been implicated in the pathophysiology of the myotoxicity associated with this pharmacotherapy. $CoQ_{10}$ and its analogue, idebenone, have been widely used in the treatment of neurodegenerative and neuromuscular disorders. These compounds could potentially play a role in the treatment of mitochondrial disorders, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, and other conditions which have been linked to mitochondrial dysfunction. This article reviews the physiological roles of $CoQ_{10}$, as well as the rationale and the role in clinical practice of $CoQ_{10}$ supplementation in different neurological diseases, from primary $CoQ_{10}$ deficiency to neurodegenerative disorders. These will help in future for treatment of patients suffering from neurodegenerative disease.

• Journal of the Chungcheong Mathematical Society
• /
• v.26 no.1
• /
• pp.147-159
• /
• 2013

Hamada ([8]) and Maruta ([17]) proved the minimum length $n_3(6,\;d)=g_3(6,\;d)+1$ for some ternary codes. In this paper we consider such minimum length problem for $q{\geq}4$, and we prove that $n_q(6,\;d)=g_q(6,\;d)+1$ for $d=q^5-q^3-q^2-2q+e$, $1{\leq}e{\leq}q$. Combining this result with Theorem A in [4], we have $n_q(6,\;d)=g-q(6,\;d)+1$ for $q^5-q^3-q^2-2q+1{\leq}d{\leq}q^5-q^3-q^2$ with $q{\geq}4$. Note that $n_q(6,\;d)=g_q(6,\;d)$ for $q^5-q^3-q^2+1{\leq}d{\leq}q^5$ by Theorem 1.2.

• Proceedings of the Korean Institute of Information and Commucation Sciences Conference
• /
• 2015.10a
• /
• pp.930-932
• /
• 2015

This study is the basic research about the patent information analysis to predict the technology trend based on the IPC(International Patent Classification) code. We investigated the patents in the field of Business Method(G06Q) since 2011. Consequently the most frequently IPC code in G06Q are as follows. G06Q 50/10(1,652), G06Q 30/02(816), G06Q 50/30(735), G06Q 40/02(713), G06Q 50/22(530), and G06Q 30/06(489).

• Bulletin of the Korean Mathematical Society
• /
• v.45 no.3
• /
• pp.419-425
• /
• 2008

For $q^5-q^3-q^2-q+1{\leq}d{\leq}q^5-q^3-q^2$, we prove the non-existence of a $[g_q(6,d),6,d]_q$ code and we give a $[g_q(6,d)+1,6,d]_q$ code by constructing appropriate 0-cycle in the projective space, where $g_q (k,d)={{\sum}^{k-1}_{i=0}}{\lceil}\frac{d}{q^i}{\rceil}$. Consequently, we have the minimum length $n_q(6,d)=g_q(6,d)+1\;for\;q^5-q^3-q^2-q+1{\leq}d{\leq}q^5-q^3-q^2\;and\;q{\geq}3$.

• Clinical and Experimental Reproductive Medicine
• /
• v.49 no.4
• /
• pp.277-284
• /
• 2022

Objective: Oxidative stress is a key player in the development of idiopathic male infertility (IMI), and various antioxidants have been used for the treatment of IMI with inconsistent results. Coenzyme Q10 (CoQ10) is a cofactor and an antioxidant that may improve semen parameters and reduce oxidative stress in patients with idiopathic oligoasthenospermia (OA). Therefore, this study aimed to explore the effect of CoQ10 on semen parameters and antioxidant markers in patients with idiopathic OA. Methods: Fifty patients with idiopathic OA and 35 fertile controls were enrolled in this prospective controlled study. All participants underwent a comprehensive fertility assessment. All patients received CoQ10 (300 mg/day) orally once daily for 3 months. Semen parameters, seminal CoQ10 levels, reactive oxygen species (ROS) levels, total antioxidant capacity (TAC), superoxide dismutase (SOD), and glutathione peroxidase (GPx) were measured in patients and controls at the start of the study and after 3 months. Results: Treatment with CoQ10 resulted in increased sperm progressive motility (p<0.05), total motility (p<0.01), seminal TAC (p<0.01), SOD (p<0.05), GPx (p<0.001), and seminal CoQ10 (p<0.001) levels and reduced ROS (p<0.01) in patients as compared to baseline. Sperm concentration and motility were also significantly correlated with antioxidant measures and seminal CoQ10 levels (r=0.38-0.57). Conclusion: CoQ10 therapy (300 mg/day for 3 months) improved sperm motility and seminal antioxidant markers in patients with idiopathic OA. Therefore, CoQ10 could be a promising treatment for patients with idiopathic infertility and may improve their fertility potential.

• Journal of the Korean earth science society
• /
• v.22 no.6
• /
• pp.500-511
• /
• 2001

For the southeastern Korea aound the Yangsan fault we measured Q$_P^{-1}$ and Q$_S^{-1}$ simultaneously by using the extended coda-normalization method for seismograms registered at 9 stations deployed by KIGAM. We analyzed 707 seismograms of local earthquakes that occurred between December 1994 and February 2000. From seismograms, bandpass filtered traces were made by applying Butterworth filter with frequency-bands of 1${\sim}$2, 2${\sim}$4, 4${\sim}$8, 8${\sim}$16 and 16${\sim}$32 Hz. Estimated Q$_P^{-1}$ and Q$_S^{-1}$ values decrease from (7${\pm}$2)${\times}$10$^{-3}$ and (5${\pm}$4)${\times}$10$^{-4}$ at 1.5 Hz to (5${\pm}$4)${\times}$10$^{-3}$ and (5${\pm}$2)${\times}$10$^{-4}$ at 24 Hz, respectively. By fitting a power-law frequency dependent to estimated values over the whole stations, we obtained 0.009 (${\pm}$0.003)f$^{-1.05({\pm}0.14)$ for Q$_P^{-1}$ and 0.004 (${\pm}$0.001)f$^{-0.75({\pm}0.14)$) for Q$_S^{-1}$, where f is frequency in Hz.

• Journal of the Korean Society of Food Science and Nutrition
• /
• v.18 no.1
• /
• pp.62-70
• /
• 1989

The present study was designed to evaluate whether supplementation of dietary coenzyme Q10 protects the ADR-induced cardiotoxicity in rats. Experiment was undertaken under the condition of simultaneous adminstration of ADR and coenzyme Q10 for 4 weeks. Adriamycin treatment significantly decreased growth performance of rats. But this decrement was not modified by dietary supplementation of conzyme Q10. In the plasma creatine phosphokinase activity, there was no significant difference among experimental groups. Electron microscopic examination revealed a progression of myocardial lesions were dependent upon the level of ADR injection. The most frequently observed fine structural alterations in rat myocardium were mitochondrial swelling, dilation of the sarcoplasmic reticulum and the appearance of a perinuclear vacuolization. But these structural changes were somewhat lesser in defree by dietary supplementation of coenzyme Q10.

• Journal of applied mathematics & informatics
• /
• v.38 no.1_2
• /
• pp.37-56
• /
• 2020

In this paper we discuss some interesting properties of (p, q)-special polynomials and derive various relations. We gain some relations between (p, q)-zeta function and (p, q)-special polynomials by considering (p, q)-analogue Euler sum types. In addition, we derive the relationship between (p, q)-polylogarithm function and (p, q)-special polynomials.